Abstract: . . .  ability to reverse cyclosporin-mediated vasoconstric- tion. Verapamil is a less potent vasodilator potentiating immunosuppression, thereby allowing to reduce cyclosporin doses. Beta-blockers have also been successfully used, either alone or in combination with dihydropyridines. Labetalol, an a- -blocker, is effective both intravenously and orally. References 1. Taler SJ, Textor SC, Canzanello VJ, Schwartz L. Cyclosporin-induced hypertension . incidence, pathogenesis and management. Drug Safety 1999;20:437-49. 2. Bennett WM, Porter GA. Cyclosporin-associated hyperten- sion. Am J Med 1988;85:131-3. 3. Faulds D, Goa KL, Benfield P. Cyclosporin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in immunoregulatory disorders. Drug 1993;45:953-1040. 4. Textor SC, Canzanello VJ, Taler . . .
. . .  incidence, pathogenesis and management. Drug Safety 1999;20:437-49. 2. Bennett WM, Porter GA. Cyclosporin-associated hyperten- sion. Am J Med 1988;85:131-3. 3. Faulds D, Goa KL, Benfield P. Cyclosporin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in immunoregulatory disorders. Drug 1993;45:953-1040. 4. Textor SC, Canzanello VJ, Taler SJ et al. Cyclosporine- induced hypertension after transplantation. Mayo Clinic Proc 1994;69:1182-93.  . . .
--1802,2,450,1596,9011